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Summary A method of carrying out region-wide audit for breast cancer was developed by collaboration between the cancer registry,
providers and purchasers as part of work to fulfill the 'Calman-Hine' recommendations. In order to test the audit method, a retrospective audit
in North Thames East compared practice in 1992 against current guidelines. The analysis compared care in specialist and non-specialist
centres. A stratified random sample comprising 28% of all breast cancer patients diagnosed in 1992 was selected from the population-based
Thames Cancer Registry. The data for 309 patients with stage I-Ill tumours were analysed by hospital type using local guidelines. No
difference between specialist (high volume) and non-specialist centres was detected for factors important in survival. Pathological staging
was good with over 70% reporting tumour size and grade. A small numberof patients were undertreated; afterconservative surgery, 10% (19)
of women did not receive radiotherapy, and 15% (8) of node-positive premenopausal women did not receive chemotherapy or ovarian
ablation. In contrast, a significant trend with hospital volume was found for several quality of life factors. These included access to a specialist
breast surgeon and specialist breast nurses, availability of fine-needle aspiration (FNA), which ranged from 84% in high-volume to 42% in
low-volume centres, and quality of surgery (axillary clearance rates ranged from 51% to 8% and sampling of less than three nodes from 3%
to 25% for high- and very low-volume centres respectively). Confidential feedback of results to surgeons was welcomed and initiated change.
The summary information gave purchasers information relevant to the evaluation of cancer services. While the audit applied present
standards to past practice, it provided the impetus for prospective audit of current practice (now being implemented in North Thames).
Keywords: breast cancer; audit of management; hospital volume; guidelines; cancer registry
The report by the EAGC (Expert Advisory Group on Cancer to the
Chief Medical Officer ofEngland and Wales, 1995) identifies the
importance ofpopulation-based monitoring ofthe standard ofcare
ofcancer patients and makes recommendations for the reorganiza-
tion of services based on skills, expertise and access to services.
The cancer registries have a key role in provision of data to assist
in planning these changes, for example data on patient volumes,
treatment patterns and outcomes.
This study explored the potential ofusing the registry's popula-
tion-based perspective and its existing network of staff and
contacts in hospitals to develop a model for breast cancer audit
across a number of providers. The audit model used current
evidence on changing and improving clinical practice (Grimshaw
et al, 1993; Haines et al, 1994). There is substantial evidence that
physicians are more likely to change theirpractice ifguidelines are
local rather than national, ifopinion leaders spread the guidelines,
if there is wide participation in the setting of standards, if there is
feedback about the results and face-to-face discussion of manage-
ment standards (Greco et al, 1993; Grimshaw et al, 1993; Haines
et al, 1994).
The work focused on breast cancer because there was strong
evidence that care could be improved. There is variation in
outcome between health authorities (Thames Cancer Registry,
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1994) and between European countries (International Agency for
Research on Cancer, 1995). A 10% improvement in 5-year
survival from 65% to 75% appears feasible (Health Committee,
1995; Sainsbury et al, 1995a; Gillis et al, 1996). Many studies in
the UK have shown variations in management of patients diag-
nosed between 1986 and 1990, several studies being in south-east
England (Basnett et al, 1992; Chouillet et al, 1994; Richards et al,
1996) and north-east England (Sainsbury et al, 1995b). There is
good evidence from randomized trials that treatment influences
outcome for breast cancer (Early Breast Cancer Trialist's
Collaborative Group, 1992).
In this paper, the audit of a retrospective sample of patients
diagnosed in 1992 is presented. The overall aim of the study was
to.develop best practice guidelines for local use to compare care in
specialist and non-specialist centres to give the impetus forgetting
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surgeons to participate in a large prospective audit. The audit
compared practice in 1992 against current (1995) guidelines for
different types ofunit and for all major aspects ofcare.
MATERIALS AND METHODS
Design of audit
There were four major stages in the audit: setting standards,
collection and analysis ofdata, confidential feedback, and discus-
sion and dissemination ofresults. The clinical aspects ofthe study
were guided by the Clinical Advisory Panel. Both the local guide-
lines and the proforma were developed with the help of the
Advisory Panel. Its members represented the medical and non-
medical specialties involved in breast cancer care, including diag-
nostic radiology, surgery, pathology, oncology, patient support and
counselling, and data management. The Panel included opinion
leaders who had represented their specialty on published breast
cancer working groups, as well as the QA surgeon from the
screening programme and local clinicians who gave a sense of
wider ownership. The guidelines were based on and referenced
existing national guidelines and authoritative evidence (NHSBSP,
1989a,b, 1993; Joint Council for Clinical Oncology, 1991, 1993,
1994; Early Breast Cancer Trialist's Collaborative Group, 1992;
Fallowfield et al, 1992; IPSH, 1993; British Breast Group, 1994;
British Association of Surgical Oncology, 1995) and included
targets for the proportion of patients expected to meet each stan-
dard. The draft standards were discussed widely to ensure local
involvement ofclinicians in the region. The data collection used a
form based on much previous experience in the Registry and
leading breast units (Chouillet et al, 1994; International Agency
for Research on Cancer, 1995). The proforma was designed to
assess adherence to the standards.
The patient sample
The study was based on the population of North Thames East
Health Region. A sample was selected randomly from all breast
cancers diagnosed in 1992, registered at Thames Cancer Registry
and treated in NHS or private hospitals within the Region. Patients
were assigned to their hospital offirst surgery or offirst referral if
they had no surgery. The hospitals were grouped according to
volume and type as described below, and the patient sample was
stratified by hospital type into five strata. As management depends
on menopausal status, and only one-fifth of breast cancer patients
are aged under 50 years at diagnosis, the patient sample was also
stratified by age into two age strata (< 50 years and 50 years and
over). In order to achieve a reasonable statistical power (80%
power, 95% confidence interval, for20% difference in proportions)
(Armitage and Berry, 1987), we required 40-50 patients in each of
the two age groups, thus about 100 in each hospital type group.
Data analysis
Data were extracted from the clinical notes onto the paper form
and then entered into a central database for analysis at the cancer
registry. The cancer registry was seen as an unbiased base suitable
for the role ofpooling the data, providing confidential feedback to
clinicians and involving all the Trusts at local level. It is a neutral
organization in the purchaser-provider split and is not linked to
any one provider. Because it has a region-wide base, all providers
were represented both within and outside the NHS. The analysis
comprised a comparison between current (1992) practice against
locally developed guidelines. Differences in the proportions of
patients observed and expected were tested using chi-squares,
95% confidence intervals and chi-squares for trend. Confidential
feedback was provided to all participating surgeons.
RESULTS
There were 36 hospitals carrying out breast cancer surgery in
1992. These were grouped into hospital types using categories of
high, medium, low and very low based on volumes of > 100,
50-99, 10-49 and 1-9 respectively. These categories were chosen
to give a reasonable number ofhospitals and patients in each cate-
gory. The five high-volume centres were all screening centres, one
being both a screening centre and a university hospital. The non-
screening university hospitals were categorized separately as they
were considered to be another type ofspecialist centre. There were
five medium-volume, eight low-volume and 15 very low-volume
hospitals, more than half of the very low-volume hospitals being
private hospitals. The volume data were obtained from Thames
Cancer Registry in 1994 when breast registrations for 1992 were
about 80% complete.
The specialist breast surgeons were identified from the cancer
registry data as those operating on 30+ new cases per year, to
correspond with the categories used in Yorkshire (Sainsbury et al,
1995a). There were 13 specialist (high-volume) surgeons, and as a
group they operated on 52% ofthe patients in North Thames East;
there were 70 surgeons operating on the remaining 48% of
patients. The volumes for non-specialists ranged from 1-29 per
year with a mean of 8.5 per year. The 13 specialist surgeons had
volumes in the range 30-124 patients per year, with a mean of 53
per year. Six of these specialist surgeons had volumes over 50 per
year. Seven of the specialist surgeons worked in the five high-
volume units, two in medium-volume units, two in groups of two
or three medium- and low-volume hospitals, and two in university
hospitals. None ofthe specialists worked in very low-volume units.
There were 2070 breast cancer patients registered at Thames
Cancer Registry, diagnosed in 1992 and resident in North Thames
East at diagnosis. The patients eligible for audit included only
those treated for a first cancer (94%) at ahospital within the region
(96%) and aged under 81 years at diagnosis (90%). A further 8%
registered only from a death certificate (DCOs) were excluded,
1480 eligible
breast cancer cases
diagnosed in 1992
resident in
North Thames East
n %
/,4 High-volume hospitals 646 44
,v Medium-volume hospitals 346 23
-- Low-volume hospitals 287 19
s Very low-volume hospitals 78 5
' Teaching hospitals 123 8
Figure 1 Eligible patients by type of hospital of surgery
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Table 1 Basic characteristics of patients and treatment
Hospital type
Teaching Very low volume Low volume Medium volume High volume Total
n % n % n % n % n % n %
Menopausal status
Pre
Peri
Post
Not known
23
2
29
1
55
Referred by
GP
Screening
Other
Not known
47
4
3
1
55
Tumour size
<15 mm
15-40 mm
>40 mm
Not known
Total
Surgery type
Excision biopsy
Wide local excision
Repeat excision
Mastectomy
Not known
Total
Axillary surgery
Sampling
Clearance
Not known
Not done
Total
Node status
Negative
Positive
Not done
Not known
Total
Tamoxifen given
Yes
No
Not mentioned
Total
Chemotherapy given
Yes
No
Not mentioned
Total
Radiotherapy given
Yes
No
Not mentioned
Total
8
14
4
29
55
6
26
0
23
0
55
15
25
1
14
55
23
14
14
4
55
38
7
10
55
13
16
26
55
32
14
9
55
42 3
4 3
53 5
2 1
12
85 9
7 1
5 1
2 1
12
15 1
25 8
7 2
53 1
12
11 0
47 6
o o
42 4
0 2
12
27 10
45 1
2 0
25 1
12
42 4
25 6
25 1
7 1
12
69 11
13 0
18 1
12
24 2
29 5
47 5
12
58 8
25 3
16 1
12
25 34
25 5
42 40
8 0
79
75 72
8 5
8 2
8 0
79
8 20
67 32
17 13
8 14
79
0 7
50 45
0 1
33 25
17 1
79
83 22
8 34
0 0
8 23
79
33 29
50 25
8 23
8 2
79
92 73
0 3
8 3
79
17 20
42 24
42 35
79
67 51
25 17
8 11
79
43 33
6 4
51 40
0 6
83
91 68
6 13
3 0
0 2
83
25 16
41 43
16 7
18 17
83
9 11
57 35
1 2
32 35
1 0
83
28 36
43 27
0 0
29 20
83
37 30
32 30
29 21
3 2
83
92 73
4 4
4 6
83
25 16
30 29
44 38
83
65 53
22 19
14 11
83
40 35
5 3
48 39
7 3
80
82 57
16 21
0 2
2 0
80
19 22
52 37
8 3
20 18
80
13 4
42 48
2 1
42 27
0 0
80
43 24
33 41
0 0
24 15
80
36 35
36 25
25 15
2 5
80
88 62
5 7
7 11
80
19 20
35 24
46 36
80
64 59
23 14
13 7
80
44 128 41
4 17 6
49 153 50
4 11 4
309
71 253 82
26 44 14
3 8 3
0 4 1
309
28 67 22
46 134 43
4 29 9
23 79 26
309
5 28 9
60 160 52
1 4 1
34 114 37
0 3 1
309
30 107 35
51 128 41
0 1 0
19 73 24
309
44 121 39
31 100 32
19 74 24
6 14 5
309
78 257 83
9 21 7
14 31 10
309
25 71 23
30 98 32
45 140 45
309
74 203 66
18 67 22
9 39 13
309
giving 1480 cases eligible for the study. The eligible patients were (stratified) random sample comprised 419 (28%) of the 1480
categorized according to hospital of first surgery as shown in eligible patients. On review ofcase notes, 19 cases were ineligible
Figure 1. Almost halfthe patients (44%) had their surgery at high- (seven not diagnosed in 1992, one with unknown primary site,
volume centres, only 5% at the very low-volume centres. The eight with prior malignancy, one duplicate registration, one never
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Table 2 Pathology report by hospital type
Hospital type
Teaching Very low volume Low volume Medium volume High volume Total
n % n % n % n % n % n %
Tumour size reported
Yes 26 47 11 92 65 82 66 80 62 78 230 74
No 29 53 1 8 14 18 17 20 18 23 79 26
Total 55 12 79 83 80 309
Grade reported
Yes 44 80 8 67 59 75 58 70 60 75 229 74
No 11 20 4 33 20 25 25 30 20 25 80 26
Total 55 12 79 83 80 309
Excision margins reported
Yes 54 98 10 83 71 90 78 94 76 95 289 94
No 1 2 2 17 8 10 5 6 4 5 19 6
Total 55 12 79 83 80 308
No. of nodes sampled
< 3 5 9 3 25 15 19 12 14 2 3 37 12
3-7 9 16 3 25 18 23 25 30 18 23 73 24
8+ 21 38 2 17 16 20 18 22 39 49 96 31
No. not known 5 9 3 25 7 9 8 10 6 8 29 9
No axillary surgery 15 27 1 8 23 29 20 24 15 19 74 24
Total 55 12 79 83 80 309
Nodal status
Positive 14 25 6 50 25 32 30 36 25 31 100 32
Negative 23 42 4 33 29 37 30 36 35 44 121 39
Not known 4 7 1 8 2 3 2 2 5 6 14 5
No axillary surgery 14 25 1 8 23 29 21 25 15 19 74 24
Total 55 12 79 83 80 309
treated in hospital and one in wrong hospital group). Eighteen of
these were successfullyreplaced from the pool ofeligiblepatients.
Of the 419 cases sampled, 358 patients' notes were traced. The
trace rate was over 90% except in university hospitals (83%) and
very low-volume hospitals (41%). Data collection was facilitated
by 16 nominated breast surgeons who covered all the main hospi-
tals in this study. For the main analyses, we excluded some cases
as the guidelines do not cover them. Those were: 19 cases (5%)
with in-situ disease only; eight cases (2%) with metastatic disease
involving spread to distant organs, such as bone, pleura, brain and
supraclavicular nodes; 21 cases who had no surgery (all but four
having a valid reason recorded, such as advanced disease or
comorbidity); and one case never treated in hospital. The
remaining 309 cases were all invasive cancers without distant
metastatic disease (i.e. stage I-III), and this group was analysed in
relation to the local guidelines.
PATIENT CHARACTERISTIC BY HOSPITAL TYPE
The 309 women in the main analysis were treated in 26 hospitals,
which included all the high-, medium- and low-volume units, the
three university hospitals and only 5 of the 15 very low-volume
hospitals. As shown in Table 1, there were about 80 patients in
each of the three main (high, medium and low volume) hospital
groups, but there were only 12 and 55 patients, respectively, in
very low-volume and university hospital groups because of fewer
eligiblepatients and difficulty in tracing case notes. The very low-
volume units included private clinics.
Table 1 shows basic descriptors of the patients in the sample,
their tumours and treatments. Forty-one per cent were pre-
menopausal, 5.5% perimenopausal, 50% post-menopausal and
3.5% with unknown menopausal status. Most patients (82%) were
referred by their GP and 14% through the screening programme.
There was a significant trend in referral from screening to the
higher volume hospitals (P-value for trend = 0.0028), suggesting
an association between early stage and high volume. This also
suggests that guidelines on referral of screen-detected cases are
being followed.
There was no significant variation between hospital types in
the proportion of women having mastectomy (37%), axillary
surgery (76%), tamoxifen (83%), chemotherapy (23%) and radio-
therapy (66%).
Staging data
Staging data, particularly tumour size, grade and nodal status are
important to be able to evaluate the appropriateness ofcare.
Table 2 shows the quality indicators for pathological reporting.
The target for reporting of tumour size was 80%; in the sample,
74% (95% CI = 70-79%) were reported, but this was significantly
poorer in theuniversity hospital group at47% (95% CI = 34-60%)
(P =0.000014). Grade was reported for 74% (95% CI = 69-79%),
within the guideline target of75%.
Reporting of nodal status was less good. The node status (posi-
tive or negative) was reported for 94% of cases having axillary
surgery, and the number of involved nodes was reported for 88%
(95% CI = 83-92%), significantly lower than the guideline target
of 100%; this was similar across all hospital types.
Assessment ofcase-mix in terms oftumour stage was limitedby
the substantial proportions without tumour size (26%) and without
axillary surgery (24%). However, among those with tumour size,
the distribution was similar in all hospital types, with 29% of
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Table 3 Women eligible for adjuvant therapies
Premenopausal Premenopausal Grade Ill or
node positive nodes unknown tumour > 3 cm
None 1 2 1
Radiotherapy (RT) 1 1 3
Tamoxifen 0 1 3
RT + Tamoxifen 6 7 8
Any combination including 44 12 24
chemotherapy or ovarian
ablation
Total 52 23 39
tumours being very small tumours ofless than 15 mm, 58% having
a diameter of 15-40 mm and 13% being large tumours of more
than 40 mm. As shown in Table 1, the high-volume centres saw
more small tumours (35%, P = 0.198) and fewer large tumours
(5%, P = 0.039), as would be expected in screening centres. This
result supports the suggestion of an inverse relation between
tumour stage and hospital volume. About 45% of women were
node positive, among those whose nodal status was known, with
very little variation by hospital types.
Surgery
Axillary surgery included both sampling and clearance (Tables 1
and 2). Axillary clearance showed a clear gradient from 51% (95%
CI = 40-62%) in 'specialist' high-volume centres to 8% (95% CI =
0-24%) in the very low-volume centres (P-value fortrend =0.019).
There was a trend in radical clearance of more than eight nodes,
from 49% (95% CI = 38-60%) in the high-volume centres to 17%
(95% CI = 0-38%) in the very low-volume centres (P-value for
trend =0.0002). The guidelines specified thatmore than three nodes
should be excised if axillary surgery was performed. At the very
low-volume centres, sampling of less than three nodes occurred in
25% (95% CI = 1-50%) of cases compared with 3% (95% CI =
0-60%) in the high-volume group (P-value for trend = 0.01).
Radical surgery (mastectomy) was recommended for all
tumours larger than 4 cm in diameter. There were only 29 patients
in the sample with large tumours, and surprisingly only 55% (95%
CI = 34-70%) had mastectomy, the remainderhaving conservative
surgery. This pattern was consistent across all hospital types and
did not correlate with actual tumour size. There may be other
factors that affect this decision, such as breast size. Conversely, a
low mastectomy rate was expected for small tumours (< 16 mm)
but the rate observed was 21% across all hospital types, perhaps
reflecting patient choice.
Undertreatment
There were small groups of women who did not receive the treat-
ments recommended in the guidelines. Those reported below are
clinically important and likely to adversely affect survival.
After conservative surgery, radiotherapy to the breast was
recommended for 95% of patients. A total of 192 women (62%)
had conservative surgery and, ofthese, 19 patients (10%, 95% CI =
6-14%) did not receive radiotherapy. This did not appear to be
linked to the presence of radiotherapy facilities on site, hospital
volume or surgeon volume but may reflect poor care in certain
units. For 5 of the 19 patients, reasons could be discerned. Three
patients refused radiotherapy (tumour sizes 3 mm, 17 mm and
35 mm), and one had a phylloides 40 mm tumour. One patient had
contraindications systemic lupus erythematosus (SLE). Fourteen
cases appeared to have been definitely eligible for radiotherapy;
two ofthese were over 70 years (one having a 50 mm tumour), two
also suffered a 2-month delay between diagnosis and treatment,
and one was under 50 years and node positive. Seven of the 14
patients were treated at teaching hospitals, and seven were
managed by high-volume surgeons.
Node-positive women should all be offered adjuvant hormones or
chemotherapy; tamoxifen was recommended for post-menopausal
women and CMF (cyclophosphamide, methotrexate and 5-fluo-
rouracil) or an equivalent regimen or ovarian ablation for
premenopausal women. For the post-menopausal women in this
sample, 152 of 153 received tamoxifen whatever their nodal status,
and so the target was met easily. However, for the 128 pre-
menopausal women, 8 (15%, 95% CI =6-25) ofthe 52patients with
positive nodes did not receive chemotherapy or ovarian
ablation, as shown in Table 3. Of the eight patients, one had
neutropenia and one refused, hence only six should have undergone
chemotherapy and did not. One ofthe six had no adjuvant therapy at
all after mastectomy for a 40 mm tumour. None of the six women
was managed in a high-volume centre, but four of the six were
managed by two high-volume surgeons. In addition, some of the
premenopausal women with unknown nodal status or with grade III
orlarge tumours (size > 3 cm), which should be treated aggressively
to improve survival, also failed to receive adjuvant chemotherapy
(Table 3). The local guidelines did not insist on axillary surgery,
because there was no local consensus on this. However, the guide-
lines did specify that patients with unknown nodal status should be
treated as node positive.
As far as could be ascertained from the case notes and the CRC
Trials Centre in London, only 29 (9%, 95% CI = 6-12%) patients
entered national multi-centre clinical trials, 18 being treated
within one district. They were managed at seven hospitals, five of
the hospitals having a high-volume surgeon, but only two being
Table 4 Fine-needle aspiration by hospital type
Hospital type
Teaching Very low volume Low volume Medium volume High volume Total
n % n % n % n % n % n %
Yes 39 71 6 50 33 42 53 64 67 84 198 64
Notdone 16 29 5 42 44 56 30 36 11 14 106 34
Notknown 0 0 1 8 2 3 0 0 2 3 5 2
Total 55 12 79 83 80 309
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Target 95% 1
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... ~~~~~~~~~I
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Figure 2 Radiotherapy after conservative surgery
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Figure 3 Fine-needle aspiration given by hospital type
hieh-volumne hospitals. Surprisingly, only five of these patients
were in the university hospital group. The oncology guidelines
included recommilendationis on participation in clinical trials. The
1ew centres actively recruiting into national trials are a good
examiiple of what can be achieved. For breast cancer, there are a
number of areas ot reial clinical uncertainty; to address these,
nationial trials have been set up by the CRC and MRC. Almost
90%/c of patients are eligible for trials, but accrual is consistently
less than 10% (Chouillet et al, 1994). Only national multicentre
trials were included in the audit.
Overtreatment
The ,guidelines specified that women should n1ot have radiotherapy
to the axilla after axillary clearance because of the increased risk
ol lymphoedema anid mor-bidity in the armii. A total of 128 (41%)
woImlenI had axillar-y clearance, and eight (6%, 95% CI = 2-10)
also had axillar-y radiotherapy. These were generally young
WIomnen; I:ost were lindeI 50 years - the oldest was 60 years - with
palpable tUmllOurS. Surprisingly. three women were node negative.
The threc youngest women were node positive, and one of these
(still alivc) received excision biopsy, wide local excision. mastec-
tomy with axillar-y clearance, tamoxifeni, radiotherapy to the axilla,
ovarian ablationl anid chemilotherapy withini a 6-month period for a
ductal. grade 11, 25-11mm11 tumllour. They were treated in five hospi-
tals, ranging froIml high to low volume.
Inappropriate use of resources
Diagnostic investigations to detect metastasis were common
despite the fact that less than 5% ofnewly presenting patients have
distant spread of disease, and the King's Fund Guidelines in 1986
recommended that these investigations were 'not usually neces-
sary' (King's Fund, 1986). Forexample, 38% of women had bone
scans; in university hospitals, this was almost 70%. Of the 118
scans performed on our 309 women, all were negative apart from
one false positive. The findings were similar for liver function
tests and liver ultrasound scans.
Variable access to services
Patients have a right to a uniformly high standard of care,
including non-invasive diagnostic techniques, prompt treatment
and support from a breast nurse specialist. We found considerable
variation in these aspects of care which may not affect survival but
are extremely important to the patient.
Fine-needle aspiration (FNA) is much less invasive than
surgical biopsy and can provide a definitive diagnosis of malig-
nancy. It is also recommended by British Association of Surgical
Oncology (BASO) (1995) as part of a triple assessment conducted
at a single visit. There was a clear gradient in the use of this tech-
nique, from 84% (95% CI = 76-92%) at the high-volume centres
down to 42% (95% CI = 31-53%) at the low-volume centres
(P = 0.000001) as shown in Table 4. Very few centres reached the
BASO target of90%. If70% is taken as an acceptable standard, all
high-volume centres achieved this, as well as three out of five of
the medium-volume centres, none of the low- and very low-
volume centres and two out of three of the university centres.
All hospital groups met the waiting times target which states
that 50% of patients should attend hospital within 14 working days
of referral by the GP. Oxerall, 50% (95% Cl = 45-56%) of new
referrals were seen within 20 calendar days. However, 15% of
patients waited more than 5 weeks for their first visit and 9% mor-e
than 7 weeks, the figures being very similar across all hospital
types. The intervals were calculated from the dates of the GP
referral letter and the first appointment; they will depend on
factors both inside and outside the breast unit, such as the postal
services. In the very low-volume group. the relevant letters were
often missing from the case notes, and so half the patients had
unknown waiting times in this group.
Waiting time from diagnosis to first surgery (or to neoadjuvant
chemotherapy or radiotherapy) was less than 2 weeks for 77%
(95% CI = 72-82%) of patients, short of the target of 90%. Some
8% of the sample waited longer than 4 weeks for first treatment.
Breast reconstruction was offered in only six hospitals in 1992.
Three of these were high-volume hospitals. Two years after diag-
nosis, only 9 (8%) out ol 114 women had received breast recon-
struction after Irastectomy.
The facilities for patient support were limited. There were
specialist breast nurses covering all high-. medium- and most low-
voluimie units. Nurses covering 15 units responded to our question-
naire about services in 1994. Ofthese, six units had no prosthetics
service, including two high-volume centres and one university
centre, and four had no lymphoedema service. The nurses ranked
prosthetics highly in importance for the patients. In addition,
several had no funds for information leaflets for patients. Lack of
space and resources were the main reasons for a limited service in
patient support.
British Journal of Cancer (1997) 75(11), 1652-1659
-
0 Cancer Research Campaign 19971658 MMa etal
Confidential feedback
The comparison between guidelines and practice in 1992 was fed
back to the 17 nominated breast surgeons participating in the study
in the format shown in Figures 2 and 3, which show the results by
hospital type and by individual hospital (anonymized) for many
aspects of practice, including those quoted above. Each surgeon
was given the code for his own hospital. Various other educational
interventions were used during the course of the study aimed at
improving practice. These are described in more detail in our
preceding paper.
DISCUSSION
It must be remembered that the audit of 1992 practice used current
(1995) guidelines (amended for local use). It did achieve its objec-
tive of generating great interest in the participating centres and
increasing the enthusiasm forcarrying out aprospective audit, rele-
vant to current practice. In addition, the results of the 1992 audit
provide evidence in the current debate about the critical mass of
patients necessary for a good quality service. Recent guidance on
this issue has been published by the Department ofHealth (Cancer
Guidance subgroup ofthe Clinical Outcomes Group, 1996).
This audit was unusually broadly based, including all the relevant
clinical specialities, using authoritative national studies and guide-
lines as the basis of the guidelines, including all types of provider
unit andinvolving theclinicians inthose units. In this audit, weused
process measures rather than outcome to assess quality of care, on
thebasis thattheresults wouldbe more reliable (Davies etal, 1995).
Unrandomized studies of outcome, such as survival rates by
hospital or by surgeon, are highly susceptible to bias. In contrast,
process is readily collected and there is a strong evidence base with
which to define best practice forbreast cancer.
The audit findings for 1992 need to be interpreted cautiously
because the number of cases was rather small and because of
possible bias due to low (41%) case trace rate in the very low-
volume group, exclusion of (8%) DCO registrations and (20%)
incompleteness ofregistration. In the very low-volume group, the
small numbers ofcases togetherwith the poorquality ofcase notes
makes interpretation difficult.
Factors influencing the importance of the findings can be
considered in three groups, according to whetherthe greatesteffect
is likely to be on survival or morbidity orpatient well-being. Most
serious is the group of factors that are likely to affect survival.
These factors included reporting of tumour size, grade and exci-
sion margins to establish the prognosis, and appropriate adjuvant
treatment. No association with hospital volume was found for
these factors for this small sample. Under-use of adjuvant treat-
ment was infrequent and was concentrated in particular units. It is
possible to extrapolate from our findings to obtain conservative
estimates of the proportion of patients whose survival may have
been adversely affected. Of 2000 new cases in 1992, 100 (5%)
cases may have missed having adjuvant radiotherapy after conser-
vative surgery, and up to 40 (2%) young women may have missed
the adjuvant chemotherapy they needed. These results have wide
confidence intervals, being based on a small sample obtained by
extrapolation from the results in each stratum. Node-positive
premenopausal patients appear more likely to be undertreated,
perhaps because they are relatively rare - about one in 10 patients
(low-volume surgeons may see less than one case per year). There
is great potential for increasing accrual into clinical trials from the
current low of 9%. Audit can have a twofold educational effect
here: firstly, to raise awareness of the need for trial participation
and, secondly, to emphasize that only major trials are going to be
large enough to provide the evidence needed to determine best
practice.
Overall, these results suggest that there was scope for a small
improvement in survival rates in the region. There was little
evidence to suggest that management factors would produce a
significant difference in survival between patients of specialist and
non-specialist surgeons. The difference in outcome found by Gillis
et al (1996) and Sainsbury et al (1995a) needs further investiga-
tion; their evidence relates to patients treated in the 1980s, the defi-
nition of 'specialist' varies, and our results suggest that there may
be bias in this outcome measure because of stage migration and
lead time bias.
In addition, there are factors that definitely affect quality oflife,
such as morbidity and patient well-being. Factors included in this
group were availability of fine-needle diagnostic cytology (FNA),
access to a specialist breast surgeon and quality of surgery as indi-
cated by number of nodes excised. These factors may possibly
affect survival, for example skilled diagnostic services should
minimize delayed diagnosis. These factors showed a significant
trend with volume, being best in the high-volume group. Two
other factors may be important in morbidity: delays and overtreat-
ment. One quarter of patients waited more than 3 weeks for their
first hospital appointment. Overtreatment of the axilla by both
clearance and irradiation, while uncommon, did occur in 3% ofthe
sample, spread through all hospital groups. A further group of
patients had axillary sampling and radiotherapy, some of whom
also risked morbidity depending on the extent and quality ofthose
treatments.
There are also factors that are very important for patient well-
being (psychological morbidity) although unlikely to affect
mortality. These are mastectomy rates, specialist nurses,
lymphoedema and prosthetics services and breast reconstruction.
The specialist nurse services were not available in most low- and
very low-volume centres. The facilities for patient support were
quite variable within each hospital group. The choice of mastec-
tomy or conservative surgery was similar for all hospital groups.
Breast reconstruction was rare in all hospital groups, and it seems
unlikely that substantial numbers of patients refused reconstruc-
tion, as up to half of patients offered immediate breast reconstruc-
tion are reported to take up this offer (Watson et al, 1995).
Practice andpattems ofreferral may have changed between 1992
and the present. The screening centres report dramatic increases in
workload but, until population-based data are complete, these
reports cannot be substantiated. There was no trend in referral
between 1991 and 1992, about 40% being referred to high-volume
centres in both years (Thames Cancer Registry data). This may be
because the screening units were all well established by 1991 in this
region. There was little evidence of trends in the use of adjuvant
chemotherapy and adjuvant radiotherapy treatment between our
1990 survey (Chouillet et al, 1994) and 1992. However, there was a
marked increase in axillary surgery from 46% in 1990 to 64% in
1992, and the NHS breast screening programme has been influen-
tial in improving pathological reporting of breast cancers, as stage
is essential for evaluation of the screening programme. Facilities
for patient support have improved greatly since 1989, when there
were very few breast care nurses (Fallowfield et al, 1992). By 1994,
there were specialist nurses covering all high-volume, medium-
volume and teaching hospitals and some low-volume hospitals.
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The results for the three university hospitals were perhaps
surprising. In most respects, they were consistent with their
(medium or low) volume group. They were atypical in low use of
tamoxifen, poor reporting of tumour size, better than average
clearance ofthe axilla, some very long waiting times for treatment
and high usage of investigations such as bone scans. Substantial
savings could be made by eliminating inappropriate investiga-
tions. These results are for patients referred first to the university
surgeon; tertiary referrals for oncology probably form the larger
part ofthe university workload and were not audited in this study.
It is extremely important forthe success and acceptability ofthis
typeofworkthatthelocal providers and surgeons feel involvement
and ownership and that they receive regular feedback and opportu-
nity fordiscussion. The registry's role as a neutral and independent
organization outside the purchaser-provider framework was a key
factor in obtaining the agreement of all providers to participate in
the study. A prospective audit of all breast patients is now being
implemented which will inform purchasers, as part of the process
of reorganizing cancer services, and will assist clinicians in tight-
ening protocols and improving care and outcome forpatients.
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